TOP TEN perturbations for NM_000270 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000270
Selected probe(set): 201695_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000270 (201695_s_at) across 5392 perturbations tested by GENEVESTIGATOR:

B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)

Relative Expression (log2-ratio):-4.097624
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs? samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal B-cell; 20uM)
MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

ovarian tumor study 17 / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):3.4609032
Number of Samples:9 / 10
Experimental ovarian tumor study 17
Human epithelial tumor cell samples from the ovary of patients with primary clear cell carcinoma. Samples were derived by laser capture microdissection (LCM).
Control normal ovarian surface epithelial cell sample
Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue from donors with non-cancerous, benign gynecological diseases.

engineered skin substitute study 2 (late) / engineered skin substitute study 1 (late)

Relative Expression (log2-ratio):-3.3893547
Number of Samples:5 / 3
Experimental engineered skin substitute study 2 (late)
Human skin substitutes tissue samples collected after 42 and 56 days after transplantation to athymic mice.
Control engineered skin substitute study 1 (late)
Human skin substitutes tissue samples collected after 14 days in culture.

B-CLL study 5 / normal bone marrow sample

Relative Expression (log2-ratio):-3.2866316
Number of Samples:441 / 74
Experimental B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

CML study 1 / B-CLL study 5

Relative Expression (log2-ratio):3.261757
Number of Samples:75 / 441
Experimental CML study 1
Bone marrow samples of patients with chronic myeloid leukemia (CML).
Control B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).

peptidoglycan study 1 / mock treated neonatal neutrophils

Relative Expression (log2-ratio):3.1736832
Number of Samples:3 / 3
Experimental peptidoglycan study 1
Healthy neonatal neutrophils with ? 99% purity isolated from cord blood samples collected after normal, full-term, vaginal delivery treated with peptidoglycan isolated from S. aureus (10 ug/ml) for 4 hours.
Control mock treated neonatal neutrophils
Healthy neonatal neutrophils with ? 99% purity isolated from cord blood samples collected after normal, full-term, vaginal delivery mock treated for 4 hours.

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal B-cell sample

Relative Expression (log2-ratio):-3.1125813
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs? samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal B-cell sample
MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

ingenol mebutate study 1 (uninvolved skin; 2d; 0.05%) / uninvolved skin sample (baseline)

Relative Expression (log2-ratio):2.9652357
Number of Samples:6 / 5
Experimental ingenol mebutate study 1 (uninvolved skin; 2d; 0.05%)
Punch biopsies of uninvolved skin obtained from actinic keratosis patients after 2 days treatment with ingenol mebutate 0.05% gel. Samples were taken one day after the second topical application with ingenol mebutate from cca 25-cm2 area of uninvolved, normal-appearing, aged but non-sun-exposed skin on the inner aspect of the upper arm. The biopsies were formalin fixed and paraffin embedded. Patients were ? 18 years of age and had two to five clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm. ATC code:
Control uninvolved skin sample (baseline)
Punch biopsies of uninvolved skin obtained from actinic keratosis (AK) patients before treatment (baseline). Samples were taken from cca 25 cm2 area of uninvolved, normal-appearing, aged but non-sun-exposed skin on the inner aspect of the upper arm. The biopsies were formalin fixed and paraffin embedded. Patients were ? 18 years of age and had two to five clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm.

cardiothoracic surgery study 1 (post) / cardiothoracic surgery study 1 (pre)

Relative Expression (log2-ratio):2.9378557
Number of Samples:5 / 5
Experimental cardiothoracic surgery study 1 (post)
Diaphragm muscle biopsies derived from patients undergoing aortic arch surgery as late in surgery as possible. Biopsies were taken from the antero-lateral aspect of the right and left diaphragm near the costal margin. All patients underwent median sternotomy and cardio-pulmonary bypass. Patients were excluded if having a history of stroke, cerebrovascular disease, spinal cord injury, progressive neuromuscular disease, NYHA III or IV cardiac disease, cardiothoracic surgery within the previous 12 weeks, history of pneumoectomy or lung surgery, scoliosis, malignancy, and FEV1 <60% of the age-predicted value.
Control cardiothoracic surgery study 1 (pre)
Diaphragm muscle biopsies derived from patients undergoing aortic arch surgery as soon as diaphragm was exposed. Biopsies were taken from the antero-lateral aspect of the right and left diaphragm near the costal margin. All patients underwent median sternotomy and cardio-pulmonary bypass. Patients were excluded if having a history of stroke, cerebrovascular disease, spinal cord injury, progressive neuromuscular disease, NYHA III or IV cardiac disease, cardiothoracic surgery within the previous 12 weeks, history of pneumoectomy or lung surgery, scoliosis, malignancy, and FEV1 <60% of the age-predicted value.

breast cancer study 40 (metastase; ovary) / ovarian tumor study 28 (clear cell adenocarcinoma)

Relative Expression (log2-ratio):-2.9373474
Number of Samples:44 / 6
Experimental breast cancer study 40 (metastase; ovary)
Metastatic tumor tissue obtained from the ovary of female patients with primary breast cancer.
Control ovarian tumor study 28 (clear cell adenocarcinoma)
Primary tumor tissue sample obtained from the ovary of female patients with clear cell adenocarcinoma.